15-1079-42

antibody from Invitrogen Antibodies

Targeting: LAMP1 CD107a

Provider product page for 15-1079-42

Flow cytometry

Other assay

Antibody data

Antibody Data
Antigen structure
References [22]
Comments [0]
Validations
Flow cytometry [1]
Other assay [9]

Submit

Product number: 15-1079-42 - Provider product page
Provider: Invitrogen Antibodies
Product name: CD107a (LAMP-1) Monoclonal Antibody (eBioH4A3), PE-Cyanine5, eBioscience™
Antibody type: Monoclonal
Antigen: Other
Description: Description: The eBioH4A3 monoclonal antibody reacts with human CD107a, also known as lysosomal-associated membrane protein-1 (LAMP-1). CD107a is a highly glycosylated protein of approximately 110kDa. It is predominantly expressed intracellularly in the lysosomal/endosomal membrane in nearly all cells. CD107a is transiently expressed on the cell surface of degranulating cytolytic T cells, and is also upregulated on the surface of activated platelets and some cancer cells. Applications Reported: This eBioH4A3 antibody has been reported for use in intracellular staining followed by flow cytometric analysis. It has also been reported for use in surface staining in a flow cytometric based degranulation assay. Applications Tested: This eBioH4A3 antibody has been pre-titrated and tested by intracellular staining and flow cytometric analysis of normal normal human peripheral blood cells. This can be used at 5 µL (0.25 µg) per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. Light sensitivity: This tandem dye is sensitive photo-induced oxidation. Please protect this vial and stained samples from light. Fixation: Samples can be stored in IC Fixation Buffer (Product # 00-822-49) (100 µL cell sample + 100 µL IC Fixation Buffer) or 1-step Fix/Lyse Solution (Product # 00-5333-54) for up to 3 days in the dark at 4°C with minimal impact on brightness and FRET efficiency/compensation. Some generalizations regarding fluorophore performance after fixation can be made, but clone specific performance should be determined empirically. Excitation: 488-561 nm; Emission: 667 nm; Laser: Blue Laser, Green Laser, Yellow-Green Laser. Filtration: 0.2 µm post-manufacturing filtered.
Reactivity: Human
Host: Mouse
Isotype: IgG
Antibody clone number: eBioH4A3
Vial size: 100 Tests
Concentration: 5 µL/Test
Storage: 4° C, store in dark, DO NOT FREEZE!

LAMP1 protein structure - 15-1079-42 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 4 The GPI biosynthetic pathway is essential to CL activation and cytolytic granule secretion. ( A ) A mixed population of WT and PIGP KO HAP1 cells was either untreated or treated with TALL-104 cells. Negative surface staining of CD55, a GPI-AP not involved in CL-mediated killing, was used as a marker for PIGP KO cells. CD55 + WT cells and CD55 - PIGP KO cells were analyzed by flow cytometry. ( B ) Percentage of WT and PIGP KO HAP1 cells in the passage control or TALL-104-treated population. ( C ) Percentage of WT and PIGP KO 786-O cells in the passage control or TALL-104-treated population. CD55 + WT cells and CD55 - PIGP KO 786-O cells were quantified by flow cytometry after each round of treatment. Data in (B) and (C) are presented as mean values ( n = 3). ( D ) Normalized surface levels of immune regulators on WT and PIGP KO HAP1 cells. ( E ) TALL-104 degranulation presented as normalized surface levels of LAMP1 on TALL-104 cells. ( F ) Normalized surface levels of TRAIL on TALL-104 cells. ( G ) Normalized surface levels of CD69 on TALL-104 cells. Data in (D) to (G) are presented as means +- SD ( n = 3). P values were calculated using Student's t test. n.s., P > 0.05. *** P < 0.001.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 5 PBRM1 regulates ULBP expression in target cells and promotes cytolytic granule secretion in CLs. ( A ) Visual representations of gene-trap insertions in the PBRM1 gene in the screens. The gray boxes indicate exons, and the gray lines indicate introns. The gray arrows depict the direction of transcription. ( B ) Immunoblot showing PBRM1 expression in WT HAP1 cells and a clonal PBRM1 KO HAP1 cell line. PBRM1 mRNA expression in these cells is shown in fig. S13. ( C ) WT (GFP + ) and PBRM1 KO (GFP - ) cells in mixed populations were quantified by flow cytometry after three rounds of passage or TALL-104 treatment. ( D ) Percentage of WT and PBRM1 KO HAP1 cells in the passage control or TALL-104-treated population. Data are presented as mean values ( n = 3). ( E ) Percentage of propidium iodide-positive WT and PBRM1 KO HAP1 cells after treatment with primary human NK cells. ( F ) Mean surface levels of immune regulators on WT and PBRM1 KO HAP1 cells. ( G ) TALL-104 degranulation presented as normalized surface levels of LAMP1 on TALL-104 cells after incubation with target cells. ( H ) NK-92 degranulation presented as normalized surface levels of LAMP1 in NK-92 cells. Data in (E) to (H) are presented as means +- SD ( n = 3). P values were calculated using Student's t test. n.s., P > 0.05. * P < 0.05, ** P < 0.01, *** P < 0.001.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 3. Cell membrane repair of cancer cells treated with 10 pulses of elevated FSS. (A) Representative PI flow cytometry scatter plots of membrane damage for DU145, PC3 and LNCaP cells after allowing 20 min of time for cell membrane repair. The percentage of the cell population in the undamaged cell gate (PI negative) is shown for each plot. (B) Average percentage of cancer cells treated with (shear stress) or without (static) 10 pulses of FSS that were undamaged after 20 min of cell membrane repair time. (C) Average proportion of undamaged cells for cell membrane damage measurements taken during FSS (damage) and for cells provided with 20 min of repair time after FSS (repair). (D) Normalized PI-negative (undamaged) cancer cells after different cell membrane repair times, ranging from 1 to 20 min. (E) Uptake of FITC-tagged 3000 MW, (F) 10,000 MW and (G) 40,000 MW dextran by cancer cells treated with or without 10 FSS pulses following 20 min of cell membrane repair. (H) Representative flow cytometry histograms of surface LAMP-1 staining. Horizontal bar indicates the LAMP-1-positive cell gate. (I) Average surface LAMP-1 expression for cancer cells treated with (hatched bars) or without (open bars) 10 pulses of FSS. Data are presented as mean+-s.d. N =3 independent experiments. * P

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 1 CD46 co-stimulation provides superior support for CTL activity. a CD46 expression on the surface of resting human CD4 + and CD8 + T cells assessed by FACS analysis ( n = 4, gating strategy in Supplementary Fig. 7a ). b Comparison of IFN-gamma, TNF-alpha and IL-10 secretion by CD3 + CD46-activated T cells. Purified CD4 + and CD8 + T cells from healthy donors were left non-activated (NA) or stimulated with immobilized antibodies to CD3, CD3 + CD28 or CD3 + CD46 and cytokines measured 60 h post activation ( n = 5). c, d Degranulation (CD107a staining, ( c )) and granzyme B expression ( d ) by CD8 + T cells upon CD46 co-stimulation. CD8 + T cells were stimulated as in ( a ) and CD107a and granzyme B expression assessed with left panels showing representative cytometry images and right panels corresponding quantifications ( n = 3, gating strategy in Supplementary Fig. 7b ). e Killing activity of CD46-activated CD8 + T cells. T cells were stimulated as depicted for 24 h and cytotoxic activity of differently activated CD8 + T cells towards DU145 target cells assessed 24 h post co-culture of T cells and DU145 cells ( n = 4, gating strategy in Supplementary Fig. 7c ). f Effect of CD46 co-stimulation on CD8 + T-cell proliferation. Purified T cells were activated as indicated for 5 days and cell proliferation measured each day ( n = 4) (black circles, non-activated cells; green, blue, and red circles, CD3, CD3 + CD28 or CD3 + CD46-activated cells, res

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 2 Autocrine CD46 engagement supports CTL activation. a Comparison of effects of TCR stimulation as well as CD28 and CD46 co-stimulation on IFN-gamma secretion by CTLs. Purified CD8 + T cells were activated with the depicted antibody combinations (for CD28 and CD46 either 1 mug/mL or 2 mug/mL at all tested CD3 stimulation conditions) for 60 h and IFN-gamma secretion measured ( n = 3). b , c Extracellular and intracellular C3aR, C3, and C3a presence in resting human CD8 + T cells. Freshly purified CD8 + T cells were either left non-permeabilized or were permeabilized and stained with antibodies to the C3aR, to C3 and C3a and evaluated by FACS ( b ) or confocal microscopy ( c , scale bar = 7 mum) for presence and localization of the respective antigens (data shown are one representative of n = 3). d , e Effects of increasing TCR and CD28 activation on C3b generation, CD107a and granzyme B expression and cytokine secretion. CD8 + T cells were left non-activated (NA) or activated with the depicted antibody combinations and C3b surface presence, CD107a and granzyme B positivity ( d , shows a representative FACS analysis of two similarly performed experiments; gray histograms, isotype controls; black histograms, non-activated cells; blue histograms, no CD28 stimulation; green and red histograms, addition of 1 or 2 mug/mL alpha-CD28, respectively) and IFN-gamma production ( e ) measured at 12 h post activation ( n = 3). The gating strategy for CD8 + T cells flow

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 3 High tumor load is associated with increased number of CD8+EOMES high T bet low cells (A, B, C) Frequency of EOMES high Tbet low of PD1+CD8+ T cells. Bone marrow cells were surface stained with anti CD3, CD4, CD8 and PD1 followed by intranuclear staining with anti-Tbet and anti-EOMES, or isotype controls ( Supplementary Figure 4A ). Gates were set on isotype controls. Figure shows % EOMES high Tbet low (A) and Tbet high EOMES low (B) of PD1+CD8+ T cells in patients with low plasma cell percentage (10 % PC). (C) % EOMES high Tbet low and Tbet high EOMES low of PD1 expressing CD8 T cells in patients with high tumor load of 40% and above. (D-G) Cytotoxic activity against autologous myeloma cells. Purified CD8+ T cells from the bone marrow of patients were co-cultured with anti CD3/CD28 beads (D) or purified, autologous myeloma cells (E) or the T cells alone (F). For the last 4 hours of the culture period, anti CD8, PD1 and CD107a or isotype controls were added as described in the Materials and Method section. Figures show the staining of isotype control (dashed lines) and CD107a (solid lines) on one representative sample of three positive ( Supplementary Figure 4C ). (G) Pooled data for cytotoxic activity (% CD107a expression) of CD8+ T cells co-cultured with autologous myeloma cells. (H, I) Proliferation of CD8+PD1+ T cells in response to autologous APCs. CFSE labeled CD3+PD1+ cells from the bone marrow of two myelo

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 5 MAVS genetic variation does not affect intracellular cytokine levels of HIV-1-specific T cells. ( a ) PBMCs of individuals carrying a MAVS minor or MAVS major genotype obtained 2.5-3.5 years p.SC were left unstimulated (-), or were treated with HIV-1 consensus B Gag peptide pool (Gag) or staphylococcal enterotoxin B (SEB). After 6 h, the percentages of surface molecules expressing CD137 + and CD107a + and intracellular expression of IFN-gamma + , IL-2 + , Mip-1beta + , and TNF-alpha + CD4 + T cells and ( b ) CD8 + T cells were analyzed using flow cytometry. Each square or dot represents a different study participant (median +- IQR). No significant differences between HIV-1-infected individuals with a MAVS minor or MAVS major genotype were observed.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig 4 Diminished polyfunctionality of A2/M158+CD8 + T cells in HLA-A2 + /B27 + individuals. ( A ) Representative FACS plots of CD107a, IFN-gamma and TNF responses of day 10 peptide-expanded CD8 + T cell lines from HLA-A2 + /non-B27 and HLA-A2 + /B27 + donors. ( B ) Pie charts representing the average fractions of expanded CD8 + T cells expressing different combinations of CD107a, IFN-gamma and TNF were generated using Pestle v1.8 and SPICE v5.35 software. Arcs represent average frequency of individual cytokines. Exact p -values are calculated using Spice permutation test (10,000) replicates. ( C ) Frequencies of the CD8 + T cell functional response producing different combinations of CD107a, IFN-gamma and TNF. Data (mean+-SEM) are pooled from blood and spleen donors over 2-3 independent experiments (n = 7-8). For each cytokine combination, statistically significant exact p -values are shown for each response ( p